Sentence: The combination of ixabepilone and bevacizumab was well tolerated , with modest activity in second - or later-line mRCC , but it is not recommended as a therapy without further clinical development .
Drug combination annotation:
[{'class': 'COMB', 'spans': ['ixabepilone', 'bevacizumab'], 'is_context_needed': True}]